Pimafucin® (Pimafucin®)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceNatamycinNatamycin
Similar drugsTo uncover
  • Natamycin
    suppositories the vagina. 
    R-PHARM, CJSC     Russia
  • Pimafucin®
    suppositories the vagina. 
    Astellas Farma Europe BV     Netherlands
  • Pimafucin®
    cream externally 
    Astellas Farma Europe BV     Netherlands
  • Pimafucin®
    pills inwards 
    Astellas Farma Europe BV     Netherlands
  • Primafungin®
    suppositories the vagina. 
    AVEKSIMA, JSC     Russia
  • Ecofucin®
    suppositories the vagina. 
    AVVA RUS, OJSC     Russia
    • Dosage form: & nbspenteric coated tablets
    Composition:

    1 tablet contains:

    Active substance: natamycin 100.0 mg;

    Excipients: potato starch 79.2 mg, povidone K30 5.0 mg, magnesium stearate 2.5 mg, lactose monohydrate 66 mg;

    shell: cellulose 18 mg, triacetin 2.7 mg, sucrose 122 mg, methyl parahydroxybenzoate 0.07 mg, calcium carbonate 30 mg, kaolin 14.2 mg, talc 21.7 mg, titanium dioxide 3 mg, acacia gum 7.3 mg, gelatin 3.3 mg, beeswax white 0.13 mg.

    Description:

    Round tablets white or almost white, coated.

    Pharmacotherapeutic group:antifungal agent.
    ATX: & nbsp

    G.01.A.A.02   Natamycin

    Pharmacodynamics:

    Antifungal polyene (tetraene) antibiotic group of macrolides. It mainly has a fungicidal effect. Natamycin irreversibly binds to the ergosterol of the cell membrane of the fungal cell, which leads to a violation of its integrity, loss of cytoplasm and cell death.Most pathogenic yeast and mold fungi are sensitive to natamycin, including delivery Candida, Aspergillus, Cephalosporium, Fusarium and Penicillium. Less sensitive to natamycin are dermatophytes and R. boydii.There have been no cases of resistance to natamycin in clinical practice. Natamycin in the form of a tablet intestinal soluble acts only in the lumen of the intestine.

    Pharmacokinetics:Natamycin is not absorbed from the gastrointestinal tract and does not have a systemic effect.
    Indications:

    - candidiasis of the intestine;

    - acute pseudomembranous and acute atrophic candidiasis in patients with cachexia,

    immune deficiency, as well as after therapy with antibiotics, corticosteroids, cytostatics;

    - sanitation of the intestinal reservoir of fungi of the genus Candida with candidiasis of the skin and mucous membranes, incl. with candidiasis vaginitis, vulvitis, vulvovaginitis.

    Contraindications:

    Hypersensitivity to the components of the drug.

    Carefully:

    Patients with a rare congenital intolerance to galactose, fructose, Lappease lactase deficiency, glucose-galactose malabsorption, or sucrose-isomaltase insufficiency should take into account that the preparation contains lactose monohydrate (66 mg) and sucrose (122 mg).

    If you have any of the listed diseases, before taking Pimafucin®, be sure to consult a doctor.

    Pimafucin® in this dosage form is not recommended for use in infants due to possible difficulty in swallowing tablets.

    Pregnancy and lactation:

    The use of Pimafucin® during pregnancy and during lactation is possible.

    Dosing and Administration:

    Inside. Eating does not affect the effectiveness of the drug.

    When candidiasis of the intestine, adults are recommended to take 1 tablet 4 times a day, children - 1 tablet 2 times a day. The average duration of the course of treatment is 1 week.

    With persistent flow of vaginitis caused by fungi of the genus Candida, together with local antifungal agents (eg, Pimafucin® suppositories) for sanitation

    foci of candidal infection in the intestines use Pimafucin® tablets (inside 1 tablet 4 times a day for 10-20 days).

    The duration of the course of treatment is set individually. After the disappearance of the symptoms of the disease is recommended to continue treatment a few more days.
    Side effects:

    On the part of the digestive system: nausea and diarrhea occur during the first days of taking the tablets and taken independently during the treatment.

    If any of the side effects listed in the manual are aggravated, or if you notice any other side effects not listed in the instructions, tell your doctor.

    Overdose:

    No cases of an overdose of Pimafucin® have been reported.

    Interaction:The interaction of the drug Pimafucin® with other drugs has not been found.
    Special instructions:not described
    Effect on the ability to drive transp. cf. and fur:Pimafucin® does not affect the ability to drive vehicles and mechanisms.
    Form release / dosage:

    Tablets coated with enteric coating 100 mg.

    For 20 tablets in a bottle of brown glass, covered with a metal screw cap.

    1 bottle per cardboard pack together with instructions for use.

    Packaging:bottles of brown glass (1) -tacks, cardboard (20)
    Storage conditions:

    Store at a temperature not exceeding 25 ° C.

    Keep out of the reach of children.

    Shelf life:

    4 years.

    Do not use after the expiration date printed on the package.

    Terms of leave from pharmacies:Without recipe
    Registration number:П N013552 / 03
    Date of registration:03.03.2009
    The owner of the registration certificate:Astellas Farma Europe BVAstellas Farma Europe BV Netherlands
    Manufacturer: & nbsp
    Representation: & nbspASTELLAS PHARMA YUROP BV ASTELLAS PHARMA YUROP BV Netherlands
    Information update date: & nbsp27.03.2014
    Illustrated instructions
      Instructions
      Up